User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa).

  1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781
  2. Evans S, Metcalfe C, Patel B et al (2010) Clinical presentation and initial management of Black men and White men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br J Cancer 102:249–254
  3. Zerbib M, Zelefsky MJ, Higano CS, Carroll PR (2008) Conventional treatments of localized prostate cancer. Urology 2:S25–S35
  4. Lebdai S, Bigot P, Azzouzi AR (2009) High-grade prostate cancer and finasteride. BJU Int. doi: 10.1111/j.1464-410X.2009.09089.x
  5. Berry WR (2005) The evolving role of chemotherapy in androgen-independent hormone-refractory prostate cancer. Urology 65:S2–S7
  6. Polascik TJ (2009) Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther 3:27–40
  7. Fujii Y, Higashi Y, Owada F, Okuno T, Mizuno H, Mizuno H (1995) Magnetic resonance imaging for the diagnosis of prostate cancer metastatic to bone. Br J Urol 75:54–58
  8. Gosfield E, Alavi A, Kneeland B (1993) Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med 34:2191–2198
  9. Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287
  10. Messiou C, Cook G, deSouza NM (2009) Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 101:1225–1232
  11. Dotan ZA (2008) Bone imaging in prostate cancer. Nat Clin Pract Urol 5:434–444
  12. Venkitaraman R, Cook GJR, Dearnaley DP et al (2009) Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer? Clin Oncol 21:39–42
  13. Ketelsen D, Röthke M, Aschoff P, Merseburger A, Lichy M, Reimold M, Claussen C, Schlemmer H.-P, Nachweis ossärer Metastasen des Prostatakarzinoms – Vergleich der Leistungsfähigkeit der Ganzkörper-MRT und der Skelettszintigrafie, 10.1055/s-2008-1027479
  14. Taoka Toshiaki, Mayr Nina A., Lee Han J., Yuh William T. C., Simonson Teresa M., Rezai Karim, Berbaum Kevin S., Factors Influencing Visualization of Vertebral Metastases on MR Imaging Versus Bone Scintigraphy, 10.2214/ajr.176.6.1761525
  15. Turner JW, Hawes DR, Williams RD (1993) Magnetic resonance imaging for detection of prostate cancer metastatic to bone. J Urol 149:1482–1484
  16. Ghanem N, Altehoefer C, Högerle S et al (2002) Comparative diagnostic value and therapeutic relevance of magnetic resonance imaging and bone marrow scintigraphy in patients with metastatic solid tumors of the axial skeleton. Eur J Radiol 43:256–261
  17. Haubold-Reuter BG, Duewell S, Schilcher BR, Marincek B, von Schulthess GK (1993) The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study. Eur J Nucl Med 20:1063–1069
  18. Carlson K., Åstrom G., Nyman R., Ahlstrom H., Simonsson B., MR Imaging of Multiple Myeloma in Tumour Mass Measurement at Diagnosis and During Treatment, 10.3109/02841859509173340
  19. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE (2005) Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 65:178–187
  20. Çiray I., Lindman H., Åström K.G.O., Bergh J., Ahlström K.H., Early response of breast cancer bone metastases to chemotherapy evaluated with MR imaging, 10.1080/028418501127346503
  21. Brown AL, Middleton G, MacVicar AD, Husband JE (1998) T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol 53:493–501
  22. Freedman GM, Negendank WG, Hudes GR, Shaer AH, Hanks GE (1999) Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer. Urology 54:118–123
  23. Traill ZC, Talbot D, Golding S, Gleeson FV (1999) Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases. Clin Radiol 54:448–451
  24. Lauenstein Thomas C., Freudenberg Lutz S., Goehde Susanne C., Ruehm Stefan G., Goyen Mathias, Bosk Silke, Debatin Jörg F., Barkhausen Jörg, Whole-body MRI using a rolling table platform for the detection of bone metastases, 10.1007/s00330-002-1344-z
  25. Bäuerle T, Hillengass J, Fechtner K et al (2009) Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 252:477–485
  26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
  27. Andersson J, Ekman P, Egevad L, Hellström M (2001) Relatively high risk of treatment failure after prostatectomy: tumour grade, histopathological stage and the preoperative serum PSA level are key prognosticators. Scand J Urol Nephrol 35:453–458
  28. Vande Berg BC, Malghem J, Lecouvet FE, Maldague B (1998) Classification and detection of bone marrow lesions with magnetic resonance imaging. Skeletal Radiol 27:529–545
  29. Vanel D, Dromain C, Tardivon A (2000) MRI of bone marrow disorders. Eur Radiol 10:224–229
  30. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
  31. Bland JM, Altman DG (2007) Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat 17:571–582
  32. Ricci C, Cova M, Kang Y S, Yang A, Rahmouni A, Scott W W, Zerhouni E A, Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton: MR imaging study., 10.1148/radiology.177.1.2399343
  33. Cumming J, Hacking N, Fairhurst J, Ackery D, Jenkins JD (1990) Distribution of bony metastases in prostatic carcinoma. Br J Urol 66:411–414
  34. Suzuki T, Shimizu T, Kurokawa K, Jimbo H, Sato J, Yamanaka H (1994) Pattern of prostate cancer metastasis to the vertebral column. Prostate 25:141–146
  35. Bubendorf L, Schöpfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583
  36. Schmidt GP, Reiser MF, Baur-Melnyk A (2009) Whole-body imaging of bone marrow. Semin Musculoskelet Radiol 13:120–133
  37. Venkitaraman R, Cook GJR, Dearnaley DP et al (2009) Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 53:241–247
  38. Schmidt GP, Reiser MF, Baur-Melnyk A (2009) Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol 70:393–400
  39. Schmidt GP, Baur-Melnyk A, Haug A et al (2009) Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Eur Radiol 19:1366–1378
  40. Takahara T, Kwee T, Kibune S et al (2009) Whole-body MRI using a sliding table and repositioning surface coil approach. Eur Radiol. doi: 10.1007/s00330-009-1674-1
Bibliographic reference Lecouvet, Frédéric ; Simon, M. ; Tombal, Bertrand ; Jamart, Jacques ; Vande Berg, Bruno ; et. al. Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa).. In: European Radiology : journal of the European Congress of Radiology, Vol. 20, no. 12, p. 2973-2982 (2010)
Permanent URL http://hdl.handle.net/2078.1/33129